Showing results (121-130 of 223) with videos related to
Sort By:
Pageof 23
Investigational New Drugs|April 22, 2011
Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trialsAntonin Levy, Laurence Albiges-Sauvin, Christophe Massard, et al.Cancer Immunology Research|April 17, 2020
Dual Relief of T-lymphocyte Proliferation and Effector Function Underlies Response to PD-1 Blockade in Epithelial MalignanciesCamille-Charlotte Balança, Clara-Maria Scarlata, Marie Michelas, et al.Clinical Colorectal Cancer|August 2, 2011
Bevacizumab combined with chemotherapy in the second-line treatment of metastatic colorectal cancer: results from the phase II BEVACOLOR studyJaafar Bennouna, Christophe Borg, Jean-Pierre Delord, et al.Investigational New Drugs|November 13, 2012
A phase I, open-label, single-arm study for QT assessment of eribulin mesylate in patients with advanced solid tumorsThierry Lesimple, Julien Edeline, Timothy J Carrothers, et al.European Journal of Cancer (Oxford, England : 1990)|August 27, 2023
Pooled Safety Analysis of Single-Agent Lurbinectedin in Patients With Advanced Solid TumoursAlexandra Leary, Ana Oaknin, José Manuel Trigo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 4, 2019
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results From the Phase II KEYNOTE-158 StudyHyun Cheol Chung, Willeke Ros, Jean-Pierre Delord, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 8, 2018
Phase Ib Trial With Birabresib, a Small-Molecule Inhibitor of Bromodomain and Extraterminal Proteins, in Patients With Selected Advanced Solid TumorsJeremy Lewin, Jean-Charles Soria, Anastasios Stathis, et al.Cancer Research|April 19, 2011
Formation of the eIF4F translation-initiation complex determines sensitivity to anticancer drugs targeting the EGFR and HER2 receptorsPierre Zindy, Yann Bergé, Ben Allal, et al.The Oncologist|August 19, 2023
Phase Ib/II Study of the Efficacy and Safety of Binimetinib (MEK162) Plus Panitumumab for Mutant or Wild-Type RAS Metastatic Colorectal CancerEric Van Cutsem, Rona Yaeger, Jean-Pierre Delord, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 19, 2009
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sitesCarlos Gomez-Roca, Christophe M Raynaud, Frederique Penault-Llorca, et al.Pageof 23